C1orf65 Inhibitors
C1orf65 inhibitors encompass a diverse set of chemical compounds that impede the functional activity of C1orf65 through various biochemical mechanisms. Histone deacetylase inhibition by Trichostatin A alters chromatin accessibility, leading to the suppression of C1orf65 expression by modifying the epigenetic environment of its gene locus. Similarly, 5-Azacytidine disrupts DNA methylation, a key epigenetic mark, thereby potentially diminishing the expression of C1orf65. Proteasome inhibition through MG-132 results in the accumulation of proteins that can negatively regulate the expression or function of C1orf65, while PI3K pathway disruption by LY 294002 may lead to decreased activation of transcription factors responsible for C1orf65 expression. The inhibition of mTOR by Rapamycin specifically targets protein synthesis of molecules involved in upregulating C1orf65, further contributing to its functional decline.
Further compounding the inhibitory landscape, PD 98059 and U0126 both function as MEK inhibitors, curtailing the MAPK/ERK pathway and in turn possibly reducing the transcriptional activity of factors that upregulate C1orf65. SB 431542's antagonism of TGF-β receptors, NF449's inhibition of Gs alpha subunit signaling, and SP600125's inhibition of JNK all contribute to a decreased transcription factor activity, which can reduce C1orf65 expression levels. BML-275 and IWP-2 target the BMP and Wnt pathways, respectively, leading to diminished activation of SMAD and beta-catenin, which are transcription factors that potentially enhance C1orf65 expression. Collectively, these inhibitors create a multifaceted approach to diminish C1orf65 activity by impinging upon various signaling pathways and regulatory mechanisms, ensuring the downregulation of this protein's functional role in the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor which can lead to changes in chromatin structure and transcription factor accessibility. These changes can diminish the expression of C1orf65 by altering the acetylation status of histones surrounding its promoter region. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor that reduces DNA methylation. By decreasing methylation at the promoter region of C1orf65, it can lead to a decrease in C1orf65 expression. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins, which can lead to the accumulation of regulatory proteins that suppress C1orf65 expression or activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor which can disrupt the PI3K/AKT pathway. Since AKT can regulate numerous proteins including transcription factors, inhibiting PI3K could lead to reduced activation of downstream targets that normally upregulate C1orf65 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which can decrease the translation of a subset of mRNAs including those that may encode proteins that upregulate C1orf65 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. The inhibition of this pathway can lead to diminished transcription factor activity and potentially lower C1orf65 expression. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB 431542 is an inhibitor of the TGF-β receptor which can lead to decreased activation of downstream SMAD transcription factors, potentially reducing the expression of C1orf65. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is also a MEK inhibitor that can suppress the ERK pathway. This suppression can result in reduced transcriptional activity of factors that enhance C1orf65 expression. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $199.00 $460.00 $1479.00 | 1 | |
NF449 is a Gs alpha subunit-specific antagonist which can inhibit G protein-coupled receptor signaling, potentially leading to decreased cAMP levels and thus diminishing transcription factors that can upregulate C1orf65. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor which can prevent the activation of AP-1 transcription factor, possibly leading to reduced expression of C1orf65. | ||||||